Case load, mortality and relapse
| Healthcare-associated cases | Community acquired cases |
| N=83 (0.9 / 10,000 inpatient bed-days)
8% MRSA
9% Age-adjusted 30-day mortality (c.f. 9% in 2018)
Relapse within 15-90 days (2019 – 2022): – 1.8% of adult events – 0% of paediatric events |
N=264 (2.8 / 10,000 population)
12% MRSA
7% Age-adjusted 30 day mortality (c.f. 16% in 2018)
Relapse within 15-90 days (2019 – 2022): – 1.3% of adult events – 0% of paediatric events |
Proportion MRSA was lower than the NSW average of 17.8% in 2022 (reference 2).
Principal clinical manifestation (source/focus)
| Healthcare-associated cases (N=83) | Community acquired cases (N=264) |
| 53% Vascular access device (e.g., intravenous cannula, central venous catheter, arterial line, tunnelled central line, subcutaneous port)
20% Skin and soft tissue infection (e.g., abscess, boil, post-operative wound infection) 7% Primary blood stream infection with no apparent primary source or clear focus |
30% Primary blood stream infection with no apparent primary source or clear focus
27% Skin and soft tissue infection (e.g., abscess, boil, deep abscess) 14 % Joint infection or spinal osteomyelitis 9% Pneumonia 7% Infective endocarditis |
References
- HNELHD_CG_23_44_Staphylococcus_aureus_bacteraemia_Management October 2023
- Australian Staphylococcus aureus Surveillance Outcome Program (ASSOP) Bloodstream Infection Report AUSTRALIAN GROUP ON ANTIMICROBIAL RESISTANCE
AIMED - Let's talk about antibiotics 